{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhao Y"],"funding":["1·3·5 project for discipline of excellence, West China Hospital, Sichuan University"],"pagination":["196-206"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10944392"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["42(2)"],"pubmed_abstract":["Patients with metastatic lung adenocarcinoma (MLA) and malignant pleural effusion (MPE) without driver gene mutations have a poor prognosis. None of the standard treatment strategies is recommended for such patients. We retrospectively analyzed the efficacy of the first-line treatment for this specific population: standard platinum-based doublet chemotherapy (CT), CT plus an immune checkpoint inhibitor (CT plus ICI), and CT plus bevacizumab (CT plus Bev). A total of 323 eligible patients were enrolled: CT alone (n = 166), CT plus Bev (n = 72), and CT plus ICI (n = 85). Treatment efficacy assessments were performed every two cycles according to the RECIST guidelines. The endpoints were overall survival (OS) and progression-free survival (PFS). Kaplan-Meier (K‒M) curves and the log-rank test"],"journal":["Investigational new drugs"],"pubmed_title":["First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?"],"pmcid":["PMC10944392"],"funding_grant_id":["ZYJC21075"],"pubmed_authors":["Duan P","Huang M","Mei T","Gong Y","Zhao Y","Liu Y","Luo Q","Long X","Zhu J","Tian X","Wang Y","Na F","Ao R"],"additional_accession":[]},"is_claimable":false,"name":"First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?","description":"Patients with metastatic lung adenocarcinoma (MLA) and malignant pleural effusion (MPE) without driver gene mutations have a poor prognosis. None of the standard treatment strategies is recommended for such patients. We retrospectively analyzed the efficacy of the first-line treatment for this specific population: standard platinum-based doublet chemotherapy (CT), CT plus an immune checkpoint inhibitor (CT plus ICI), and CT plus bevacizumab (CT plus Bev). A total of 323 eligible patients were enrolled: CT alone (n = 166), CT plus Bev (n = 72), and CT plus ICI (n = 85). Treatment efficacy assessments were performed every two cycles according to the RECIST guidelines. The endpoints were overall survival (OS) and progression-free survival (PFS). Kaplan-Meier (K‒M) curves and the log-rank test","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-27T03:17:36.055Z","creation":"2025-04-06T17:27:19.626Z"},"accession":"S-EPMC10944392","cross_references":{"pubmed":["38386170"],"doi":["10.1007/s10637-024-01424-4"]}}